Studying Kratom and other opioid-like drugs

Paula N. Brown, director of applied research at BCIT and an adjunct professor of biology at UBC, weighed in on the U.S. FDA recommendation to effectively ban Kratom and its alkaloids.

“The FDA should consider that Kratom fits right into the current push in Washington to allow for creative approaches for treatment of pain and opioid addiction,” she wrote in an op-ed for The Hill. “It is in the interest of public health to take an approach to regulating Kratom products that permits ongoing access to Kratom but with oversight as is provided for other dietary supplements.”